Skip to main content
. Author manuscript; available in PMC: 2016 Mar 18.
Published in final edited form as: FEBS Lett. 2009 May 3;583(12):1933–1938. doi: 10.1016/j.febslet.2009.04.039

FIGURE 7. Abundance of inflammatory mediator mRNAs in LPS-treated wild-type and TTP−/- BMDM.

FIGURE 7

A) BMDM derived from wild-type and TTP−/− littermate mice were left untreated or pretreated for 1h with 5 μM SB 202190. Some cells were treated with LPS for a further 4h. Cells were harvested, lysed and RNA was extracted and analysed by northern blotting for TNF and COX-2 mRNAs. B) Cells were left untreated or pretreated for 30 min with an anti-TNF neutralising antibody and then treated with 5 μM SB 202190 or vehicle control (0.1% DMSO) for 1h, followed by LPS treatment for a further 4h. Cells were harvested, lysed and RNA was extracted and analysed by RPA as before. Similar results were obtained in two independent experiments. C) Plot of mean cytokine mRNA in TTP−/− BMDM normalised to GAPDH mRNA expressed as fold change of that in wild-type cells treated with LPS for 4h ± S.E.M. from three independent experiments.